A BREAKTHROUGH TECHNOLOGY DESIGNED TO PRESERVE SIGHT AND HALTING VISION LOSS ASSOCIATED WITH A RANGE OF RETINAL DISEASE BY PREVENTING THE DEATH OF KEY RETINAL CELLS .

I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments.

We develop an innovative therapeutic approach protected by 4 patents and with a lead program to treat Acute Liver Failure and a second program to preserve sight and halting vision loss associated with a range of retinal disease by preventing the death of key retinal cells.

We are developing a first-in-class drug based on a dual-targeted approach, capable of stopping directly and simultaneously two forms of regulated cell death pathways known to be involved in triggering of numerous acute and chronic pathologies and contributing to organ damage. Our molecule protects the cells, prevents tissue damage, and finally preserves and restores organ function.

SeaBeLife is the only company worldwide developing such a therapeutic approach.

Our molecule has a direct protective effect on cells and has the potential to prevent evolution to severe life-threatening form. We have already obtained very convincing in vivo results in several highly predictive models. Our molecules were tested on pharmacologically relevant murine models and have shown no toxicity and strong efficacy.

SeaBeLife is composed of an experienced and complementary operational team managing by two women and supported by a scientific and strategic advisory board with scientific and medical experts of extensive expertise in drug development.

We have already raised 4.3M€ to develop our technology and we are ready to bring our molecules to the clinic and validate its safety and efficacy.

The main milestones over the next 2-years will be the production of compliant clinical batches and the realization of phase 1 and phase 2a clinical trials.

The WomenTechEU award and funding will allow us to gain visibility as women entrepreneurs and also to take an important step in our pre-clinical development for eye diseases.